CX3CR1 drives cytotoxic CD4+CD28- T cells into the brain of multiple sclerosis patients

Journal of Autoimmunity

Volumn 38, Issue 1, 2012, Pages 10-19

  Broux, Bieke ^a   Pannemans, Kim ^a   Zhang, Xin ^b   Markovic Plese, Silva ^b   Broekmans, Tom ^a,c   Eijnde, Bert O ^a,c   Van Wijmeersch, Bart ^a,c,d,e   Somers, Veerle ^a   Geusens, Piet ^a,f   van der Pol, Susanne ^g   van Horssen, Jack ^g   Stinissen, Piet ^a   Hellings, Niels ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PHL University College   (Belgium)

^d Mariaziekenhuis Noord Limburg ^*  (Belgium)

^e Revalidatie and MS Centrum   (Belgium)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CX3CR1; Fractalkine; Immunosenescence; Multiple sclerosis; T cells

Indexed keywords

AUTOANTIGEN; BETA INTERFERON; CASPASE 3; CHEMOKINE RECEPTOR CX3CR1; CORTICOSTEROID; FRACTALKINE; IMMUNOGLOBULIN; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN; CELL GRANULE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE DURATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE MIGRATION; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PHENOTYPE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STIMULUS RESPONSE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; BRAIN; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CX3CL1; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 84856650320     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.006     Document Type: Article

References (66)

1. Effros R.B. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 1997, 21:471-478.
2. Vallejo A.N., Brandes J.C., Weyand C.M., Goronzy J.J. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. JImmunol 1999, 162:6572-6579.
3. Schmidt D., Goronzy J.J., Weyand C.M. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. JClin Invest 1996, 97:2027-2037.
4. Sun Z., Zhong W., Lu X., Shi B., Zhu Y., Chen L., et al. Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells. JClin Immunol 2008, 28:464-472.
5. Moosig F., Csernok E., Wang G., Gross W.L. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998, 114:113-118.
6. Pandya J.M., Fasth A.E., Zong M., Arnardottir S., Dani L., Lindroos E., et al. Expanded TCR-Vbeta restricted T cells from sporadic inclusion body myositis patients are proinflammatory and cytotoxic CD28(null) T cells: cD28null T Cells in Sporadic Inclusion Body Myositis. Arthritis Rheum 2010.
7. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. JClin Invest 1998, 101:725-730.
8. Scholz C., Patton K.T., Anderson D.E., Freeman G.J., Hafler D.A. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. JImmunol 1998, 160:1532-1538.
9. Markovic-Plese S., Cortese I., Wandinger K.P., McFarland H.F., Martin R. CD4+CD28- costimulation-independent T cells in multiple sclerosis. JClin Invest 2001, 108:1185-1194.
10. Ebers G.C., Kukay K., Bulman D.E., Sadovnick A.D., Rice G., Anderson C., et al. Afull genome search in multiple sclerosis. Nat Genet 1996, 13:472-476.
11. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. NEngl J Med 2007, 357:851-862.
12. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007, 39:1083-1091.
13. Weber F., Fontaine B., Cournu-Rebeix I., Kroner A., Knop M., Lutz S., et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008, 9:259-263.
14. Broux B., Hellings N., Venken K., Rummens J.L., Hensen K., Van Wijmeersch B., et al. Haplotype 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants. Genes Immun 2010, 11:326-333.
15. Ben Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981, 11:195-199.
16. Vandenbark A.A., Gill T., Offner H. Amyelin basic protein-specific T lymphocyte line that mediates experimental autoimmune encephalomyelitis. JImmunol 1985, 135:223-228.
17. Gay D., Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991, 114(Pt 1B):557-572.
18. Vos C.M., Geurts J.J., Montagne L., van Haastert E.S., Bo L., van d., et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis 2005, 20:953-960.
19. Stoll G., Kleinschnitz C., Meuth S.G., Braeuninger S., Ip C.W., Wessig C., et al. Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging. JCereb Blood Flow Metab 2009, 29:331-341.
20. Man S., Ubogu E.E., Ransohoff R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 2007, 17:243-250.
21. Mahad D.J., Howell S.J., Woodroofe M.N. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. JNeurol Neurosurg Psychiatry 2002, 72:498-502.
22. Bartosik-Psujek H., Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005, 12:49-54.
23. Bartosik-Psujek H., Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. JNeural Transm 2005, 112:797-803.
24. McCandless E.E., Piccio L., Woerner B.M., Schmidt R.E., Rubin J.B., Cross A.H., et al. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol 2008, 172:799-808.
25. Sellebjerg F., Bornsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
26. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. JNeuroimmunol 1998, 84:238-249.
27. Krumbholz M., Theil D., Steinmeyer F., Cepok S., Hemmer B., Hofbauer M., et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. JNeuroimmunol 2007, 190:72-79.
28. Kastenbauer S., Koedel U., Wick M., Kieseier B.C., Hartung H.P., Pfister H.W. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. JNeuroimmunol 2003, 137:210-217.
29. Yano R., Yamamura M., Sunahori K., Takasugi K., Yamana J., Kawashima M., et al. Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients. Acta Med Okayama 2007, 61:89-98.
30. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. Anew class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
31. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. JExp Med 1998, 188:1413-1419.
32. Nishiyori A., Minami M., Ohtani Y., Takami S., Yamamoto J., Kawaguchi N., et al. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett 1998, 429:167-172.
33. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998, 95:10896-10901.
34. Hulshof S., van Haastert E.S., Kuipers H.F., van den Elsen P.J., De Groot C.J., van d., et al. CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. JNeuropathol Exp Neurol 2003, 62:899-907.
35. Hatori K., Nagai A., Heisel R., Ryu J.K., Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. JNeurosci Res 2002, 69:418-426.
36. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.
37. Schulz O., Jaensson E., Persson E.K., Liu X., Worbs T., Agace W.W., et al. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. JExp Med 2009, 206:3101-3114.
38. Harrison J.K., Jiang Y., Wees E.A., Salafranca M.N., Liang H.X., Feng L., et al. Inflammatory agents regulate invivo expression of fractalkine in endothelial cells of the rat heart. JLeukoc Biol 1999, 66:937-944.
39. Lucas A.D., Chadwick N., Warren B.F., Jewell D.P., Gordon S., Powrie F., et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells invivo. Am J Pathol 2001, 158:855-866.
40. Nanki T., Imai T., Nagasaka K., Urasaki Y., Nonomura Y., Taniguchi K., et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:2878-2883.
41. Kobayashi T., Okamoto S., Iwakami Y., Nakazawa A., Hisamatsu T., Chinen H., et al. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007, 13:837-846.
42. Goronzy J.J., Weyand C.M. Rheumatoid arthritis. Immunol Rev 2005, 204:55-73.
43. Deibler G.E., Martenson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972, 2:139-165.
44. Rubio V., Stuge T.B., Singh N., Betts M.R., Weber J.S., Roederer M., et al. Exvivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003, 9:1377-1382.
45. Suni M.A., Maino V.C., Maecker H.T. Exvivo analysis of T-cell function. Curr Opin Immunol 2005, 17:434-440.
46. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. NEngl J Med 2000, 343:898-904.
47. Thewissen M., Somers V., Venken K., Linsen L., van Paassen P., Geusens P., et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol 2007, 123:209-218.
48. Thewissen M., Somers V., Hellings N., Fraussen J., Damoiseaux J., Stinissen P. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. JImmunol 2007, 179:6514-6523.
49. Miyazaki Y., Iwabuchi K., Kikuchi S., Fukazawa T., Niino M., Hirotani M., et al. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis. Mult Scler 2008, 14:1044-1055.
50. Sawai H., Park Y.W., Roberson J., Imai T., Goronzy J.J., Weyand C.M. Tcell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005, 52:1392-1401.
51. Cotter R., Williams C., Ryan L., Erichsen D., Lopez A., Peng H., et al. Fractalkine (CX3CL1) and brain inflammation: implications for HIV-1-associated dementia. JNeurovirol 2002, 8:585-598.
52. Sunnemark D., Eltayeb S., Nilsson M., Wallstrom E., Lassmann H., Olsson T., et al. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. JNeuroinflammation 2005, 2:17.
53. Dopp J.M., Breneman S.M., Olschowka J.A. Expression of ICAM-1, VCAM-1, L-selectin, and leukosialin in the mouse central nervous system during the induction and remission stages of experimental allergic encephalomyelitis. JNeuroimmunol 1994, 54:129-144.
54. Matsuda M., Tsukada N., Koh C.S., Iwahashi T., Shimada K., Yanagisawa N. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in the spinal cord of rats during acute experimental allergic encephalomyelitis. Autoimmunity 1994, 19:15-22.
55. Bo L., Peterson J.W., Mork S., Hoffman P.A., Gallatin W.M., Ransohoff R.M., et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. JNeuropathol Exp Neurol 1996, 55:1060-1072.
56. Bullard D.C., Hu X., Schoeb T.R., Collins R.G., Beaudet A.L., Barnum S.R. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. JImmunol 2007, 178:851-857.
57. Cayrol R., Wosik K., Berard J.L., Dodelet-Devillers A., Ifergan I., Kebir H., et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008, 9:137-145.
58. Bahbouhi B., Berthelot L., Pettre S., Michel L., Wiertlewski S., Weksler B., et al. Peripheral blood CD4+T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. JLeukoc Biol 2009, 86:1049-1063.
59. Saikali P., Antel J.P., Newcombe J., Chen Z., Freedman M., Blain M., et al. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. JNeurosci 2007, 27:1220-1228.
60. Vergelli M., Hemmer B., Muraro P.A., Tranquill L., Biddison W.E., Sarin A., et al. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. JImmunol 1997, 158:2756-2761.
61. Antel J.P., McCrea E., Ladiwala U., Qin Y.F., Becher B. Non-MHC-restricted cell-mediated lysis of human oligodendrocytes invitro: relation with CD56 expression. JImmunol 1998, 160:1606-1611.
62. Nakajima T., Schulte S., Warrington K.J., Kopecky S.L., Frye R.L., Goronzy J.J., et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002, 105:570-575.
63. Goronzy J.J., Weyand C.M. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009, 11:249.
64. Van Leeuwen E.M., Remmerswaal E.B., Vossen M.T., Rowshani A.T., Wertheim-van Dillen P.M., van Lier R.A., et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. JImmunol 2004, 173:1834-1841.
65. Fletcher J.M., Vukmanovic-Stejic M., Dunne P.J., Birch K.E., Cook J.E., Jackson S.E., et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. JImmunol 2005, 175:8218-8225.
66. Casazza J.P., Betts M.R., Price D.A., Precopio M.L., Ruff L.E., Brenchley J.M., et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. JExp Med 2006, 203:2865-2877.